Lercanidipina Accord (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium‑mediated contraction, causing vasodilation, decreasing peripheral resistance, and ultimately lowering systemic blood pressure.

The appropriate dose of lercanidipine is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Dosage adjustments are made individually; patients should follow the prescriber’s instructions exactly.

Safety data for lercanidipine in pregnancy are limited, and the drug is generally not recommended unless the potential benefit outweighs the risk. It is also excreted in breast milk, so use during lactation should be avoided or closely supervised by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with potentially fewer dose‑related side effects, though individual response varies.

Store the product at room temperature, preferably below 25 °C. Keep the tablets in their original blister pack or container, protect them from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Lercanidipina Accord is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include severe hypotension, myocardial infarction, angioedema, and hepatic injury. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, swelling of the face or throat, or signs of liver dysfunction such as jaundice.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or cardiogenic shock, as the vasodilatory effect may worsen these conditions.